Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are antidiabetic agents that provide cardiovascular and renal protective effects beyond glycemic control (8, 9), and emerging evidence suggests potential neuroprotective benefits, reducing the risk of dementia and mortality in older adults (10, 11). Here, SLC5A2 is linked to dementia.